FdaApplication
NDA 022525
Identifiers
- fda_app_no: NDA022525
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2010-06-21 |
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NAMENDA XR | MEMANTINE HYDROCHLORIDE | 21MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE, EXTENDED RELEASE;ORAL |
| NAMENDA XR | MEMANTINE HYDROCHLORIDE | 7MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE, EXTENDED RELEASE;ORAL |
| NAMENDA XR | MEMANTINE HYDROCHLORIDE | 28MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE, EXTENDED RELEASE;ORAL |
| NAMENDA XR | MEMANTINE HYDROCHLORIDE | 14MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE, EXTENDED RELEASE;ORAL |
4 products